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Conclusion: The Sentinel™ surface imaging device is a 
reproducible and consistent system able to detect 
misalignments with accuracy. This study shows good 
agreement between the surface scanner and CBCT in patient 
positioning. The Sentinel™ surface imaging system is a good 
supplement to the CBCT system for accurate set-up for 
fractions for whole breast irradiation after conservative 
surgery. 
 
Poster Viewing : 4: Physics: Treatment planning: 
applications III  
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Purpose or Objective: Radiotherapy dose escalation using a 
simultaneous integrated boost (SIB) is predicted to improve 
local tumour control in oesophageal cancer patients (Warren 
IJROBP 2014), yet any increase in acute bone marrow toxicity 
could reduce treatment intensity, and limit any predicted 
improvement in patient outcome. In the SCOPE oesophageal 
trial, 28% of patients treated with concurrent 
cisplatin/capecitabine and 50 Gy in 25 fractions experienced 
grade ≥3 haematological toxicity (HT3+) (Crosby Lancet Oncol 
2013). Proton therapy has been shown to significantly reduce 
haematological toxicity in lung cancer patients receiving 
concurrent chemotherapy (Komaki Radiother Oncol 2011); we 
investigate the potential of bone marrow sparing with 
protons compared to photons, in radiotherapy dose 
escalation for oesophageal tumours. 
 
Material and Methods: 21 mid-oesophageal cancer patients 
with their original conformal plan (3D50) (chosen to be a 
representative subset of the SCOPE trial) were used to study 
the bone marrow dose delivered. A surrogate for bone 
marrow was created by outlining the thoracic vertebrae, 
sternum, scapulae, ribs and clavicles using the automatic 
thresholding tool in Eclipse (Varian). Additional plans were 
created retrospectively: a volumetric modulated arctherapy 
plan (VMAT50) with the same dose as 3D50. SIB plans with a 
dose prescription of 62.5 Gy to the high risk sub-region within 
the planning treatment volume were created using VMAT 
(VMAT62.5) and proton therapy plan (IMPT62.5). Bone V20 Gy 
and V10 Gy dose-metrics were recorded and compared across 
all plans using the Wilcoxon test and Holm Bonferroni 
correction for multiple testing. Parameters from 
gynaecological cancers (Bazan IJROBP 2012) were used to 
predict normal tissue complication probability (NTCP) of 
HT3+. 
 
Results: 3D50 plans show the highest NTCP and V20 values 
for each patient. There is no significant difference between 
the VMAT50 and VMAT62.5 plans, although VMAT plans may 
cause a larger bone volume to be irradiated below 10 Gy than 
3D50. IMPT62.5 showed significant sparing for both V10 and 
V20 and much reduced NTCP 
 
 
 
Conclusion: Proton therapy plans show significant dose 
sparing for bone marrow in the 10-20 Gy dose region thought 
to be correlated with toxicity. These plans are predicted to 
reduce the risk of HT3+ by ~50% compared to photon 
techniques, and could therefore improve treatment efficacy 
of concurrent chemoradiotherapy for oesophageal cancers. 
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Purpose or Objective: The aim of the study was to evaluate 
how the dosimetric benefit of intensity-modulated proton 
therapy (IMPT) translates into estimated toxicity risk 
reduction in patients with locally advanced non-small cell 
lung cancer (NSCLC). In addition, the potential to spare the 
heart with protons and photons was explored.  
 
Material and Methods: Five patients with NSCLC were 
treated with concurrent chemoradiation, using standard lung-
sparing photon volumetric-modulated arc therapy (L-VMAT) 
to 60 Gy in 25 fractions. Three additional treatment plans 
were created for each patient: heart-sparing VMAT (H-VMAT), 
worst-case robust heart-sparing IMPT (H-IMPT), and worst-
case robust lung-sparing IMPT (L-IMPT). Doses to the organs 
at risk (heart, lung) were evaluated. Resulting normal tissue 
complication probability (NTCP) values for radiation 
pneumonitis were estimated using the dose-only QUANTEC 
model and the adjusted QUANTEC model including clinical 
risk factors 1.  
 
Results: With IMPT, both H-IMPT and L-IMPT, DVH parameters 
including the mean lung dose (MLD), the lung volume 
receiving ≥20 Gy (V20L), the mean heart dose (MHD), and the 
volume of the heart receiving ≥30 Gy (V30H) were all 
between 32 – 80% lower compared with L-VMAT (Tab 1). 
Furthermore, at these considerably lower dose levels with 
protons vs photons, the amount of dose redistributed to the 
lungs when the heart was particularly spared was still lower 
with protons (H-IMPT vs L-IMPT: 65% decrease MHD, 11% 
increase MLD), compared with photons (H-VMAT vs L-VMAT: 
62% decrease MHD, 28% increase MLD). Using the dose-only 
QUANTEC model, comparing L-VMAT with L-IMPT, the lung-
dose reductions translated into a reduction in the risk of 
symptomatic radiation pneumonitis between 4.5% to 9.2% 
(average, 5.8%). However, the QUANTEC model adjusted for 
a priori clinical risk factors showed a reduction of 
symptomatic radiation pneumonitis risk in patients without 
clinical risk factors by 2.5% to 5.4% (average, 3.3%) in 
contrast to 14.2% to 26.7% (average, 18.2%) risk reduction in 
patients with the highest a priori risk (Fig 1). For identical 
DVH reductions, and assuming a threshold risk reduction of ≥ 
10% for G2-toxicity required for indicating proton therapy, an 
